Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 131, Issue 3, Pages 338-340Publisher
WILEY
DOI: 10.1111/j.1365-2141.2005.05777.x
Keywords
rituximab; chlorambucil; mantle cell lymphoma; B-cell non-Hodgkin lymphoma; immuno-chemotherapy
Categories
Ask authors/readers for more resources
We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression-free survival for responders was 26 months (95% CI, 4-48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available